Mapatumumab: Phase II data

A Phase II trial to treat advanced MM showed that mapatumumab plus Velcade bortezomib missed the co-primary endpoints of significantly improving disease response and PFS vs. Velcade alone. As a result, Human Genome said it does not plan to continue development of the combination for the indication. Mapatumumab was well tolerated. In March, Human Genome reported data from a Phase II trial for first-line treatment of advanced non-small cell lung cancer (NSCLC) showing that mapatumumab plus carboplatin and paclitaxel led to no difference in disease response or PFS vs. carboplatin and paclitaxel alone (see BioCentury, March 22). ...